Non-small cell lung cancer, MET-mutated

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Page editor Section editor
Singhi Eric.jpeg
Eric K. Singhi, MD
MD Anderson Cancer Center
Houston, TX

Social-twitter-icon.png esinghimd
Amit Kulkarni.jpg
Amit Kulkarni, MBBS
University of Minnesota
Minneapolis, MN

Social-twitter-icon.png AmitKulkarniMD

Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.

2 regimens on this page
2 variants on this page


Metastatic disease

Capmatinib monotherapy

back to top

Regimen

FDA-recommended dose
Study Years of enrollment Evidence
Wolf et al. 2020 (GEOMETRY mono-1) NR Phase II (RT)

Biomarker eligibility criteria

  • MET exon 14 skipping alterations

Targeted therapy

Continued indefinitely

References

  1. GEOMETRY mono-1: Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. link to original article contains protocol PubMed NCT02414139

Tepotinib monotherapy

back to top

Regimen

Study Years of enrollment Evidence
Paik et al. 2020 (VISION) 2016-2020 Phase II (RT)

Note: the FDA-recommended dose is 450 mg PO once per day; the dose here was the dose reported in VISION.

Biomarker eligibility criteria

  • MET exon 14 skipping alterations

Targeted therapy

Continued indefinitely

References

  1. VISION: Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 Sep 3;383(10):931-943. Epub 2020 May 29. link to original article contains verified protocol PubMed NCT02864992